Proton Pump Inhibitors and H2 Blockers
Key Points
- PPIs (omeprazole, pantoprazole) irreversibly block the H⁺/K⁺-ATPase proton pump — more potent, longer-lasting acid suppression.
- H2 blockers (famotidine) competitively block H2 receptors on parietal cells — suppress basal and nocturnal acid secretion.
- Antacids (calcium carbonate, aluminum/magnesium combinations) rapidly neutralize acid but require spacing from other medications.
- Sucralfate forms an adherent protective barrier over ulcer sites and is given on an empty stomach with strict medication-spacing rules.
- Misoprostol prevents NSAID-induced ulcers by reducing acid/pepsin and increasing mucosal defenses; avoid in pregnancy.
- PPIs must be taken 30–60 minutes before breakfast (delayed-release tablets); swallow whole — do not crush or chew.
- Indications: GERD, peptic ulcer disease, erosive esophagitis, H. pylori treatment adjunct, stress ulcer prophylaxis.
- In active high-acuity GI bleeding with NPO restriction, IV PPI pathways are commonly used until oral transition is safe.
- Long-term PPI use risks: hypomagnesemia, C. difficile infection, vitamin B12 malabsorption.
Mechanism Comparison
| Feature | H2 Blockers | Proton Pump Inhibitors (PPIs) |
|---|---|---|
| Target | H2 receptors on parietal cells | H⁺/K⁺-ATPase (proton pump) in parietal cells |
| Acid suppression | Suppresses basal + nocturnal acid | Blocks all basal and stimulated acid |
| Reversibility | Reversible competitive blockade | Irreversible enzyme inhibition |
| Potency | Less potent | More potent |
| Onset | Faster onset of action | May take several days for full effect |
Drug Examples
Proton Pump Inhibitors
| Drug | Key Administration Points |
|---|---|
| Omeprazole (Prilosec) | 20 mg once daily; take 30–60 min before breakfast; swallow whole |
| Pantoprazole (Protonix) | 40 mg once daily; delayed-release tablet taken whole; granules: mix in apple juice/applesauce only |
| Esomeprazole (Nexium) | 20–40 mg once daily; if capsule opened, mix pellets in applesauce — do NOT chew |
| Lansoprazole (Prevacid) | 15 mg once daily; take 30 min before meal; acid symptom relief in ~1 week |
H2 Receptor Antagonists
| Drug | Key Administration Points |
|---|---|
| Famotidine (Pepcid) | 20 mg twice daily; available oral and IV; take 10–60 min before meals for heartburn |
| Cimetidine (Tagamet HB) | 400 mg 4×/day; reduce dose in significant renal impairment (for example CrCl below about 30 mL/min); IV: infuse over 15–20 min (never rapid bolus — arrhythmia/hypotension risk) |
| Nizatidine (Axid) | 150 mg twice daily; significantly reduces nocturnal acid for 12 hours |
Note: Ranitidine was recalled and is no longer available.
Additional Hyperacidity Agents
Antacids
| Drug | Key Administration Points |
|---|---|
| Calcium carbonate | Chew thoroughly if chewable; follow with full glass of water; separate from other medications by about 1–2 hours; use caution with renal disease (hypercalcemia risk) |
| Aluminum/magnesium combinations | Often taken after meals and at bedtime; shake liquid formulations well; take with water; use caution in kidney disease or magnesium-restricted contexts |
Clinical notes:
- Antacids rapidly improve heartburn/acid-indigestion symptoms but do not heal severe mucosal injury alone.
- Calcium-carbonate withdrawal can be associated with rebound hyperacidity in some clients.
Mucosal Protectants
| Drug | Key Administration Points |
|---|---|
| Sucralfate | Typical antiulcer regimen is 1 g orally 4 times/day (about 60 min before meals and at bedtime); separate antacids by about 30 min before/after and separate quinolones/digoxin/phenytoin/tetracycline by at least 2 hours; caution in chronic renal failure or dialysis due to aluminum retention risk |
Prostaglandin Analogue
| Drug | Key Administration Points |
|---|---|
| Misoprostol | Used for NSAID-ulcer prevention; usually given with food 4 times/day (200 mcg, reduce to 100 mcg if not tolerated); contraindicated in pregnancy because uterine contractions can cause fetal harm |
Antiflatulent
| Drug | Key Administration Points |
|---|---|
| Simethicone | Commonly dosed after meals and at bedtime; shake liquid drops before dosing; often combined with OTC antacid products; generally considered safe for infant use |
Indications
- GERD (gastroesophageal reflux disease) — primary indication
- Peptic ulcer disease (gastric and duodenal ulcers)
- Erosive esophagitis — healing and prevention
- H. pylori eradication — PPIs used as adjunct to antibiotic triple therapy
- Stress ulcer prophylaxis — in ICU patients, mechanically ventilated patients
- Postoperative stress-ulcer prophylaxis in selected high-risk clients
- NSAID-induced gastric ulcer prevention (omeprazole)
- Zollinger-Ellison syndrome — hypersecretory states
- Perioperative aspiration prophylaxis — famotidine
Adverse Effects and Nursing Considerations
Short-Term Effects (Both Classes)
- Headache, dizziness, nausea, vomiting, diarrhea, abdominal pain
- H2 blockers can also produce CNS/mental-status effects and, rarely, clinically important rhythm disturbances.
- Sucralfate adverse patterns can include constipation/diarrhea, flatulence, nausea, insomnia, rash, and dizziness.
- Misoprostol adverse patterns can include diarrhea/abdominal pain, dysmenorrhea or spotting, uterine cramping, and postmenopausal bleeding.
Long-Term PPI Risks (>8 weeks)
- Hypomagnesemia — monitor magnesium with prolonged use
- C. difficile infection risk — reduced gastric acid allows pathogen survival
- Vitamin B12 malabsorption — gastric acid required for B12 absorption
- Osteoporosis risk — calcium absorption impaired
- Possible cognitive-risk association — some cohort data suggest higher dementia risk with cumulative use; interpret cautiously and reassess necessity of prolonged therapy.
- Pneumonia association — prolonged PPI exposure has observational association with increased pneumonia risk.
- Agent-specific micronutrient issues — prolonged IV pantoprazole can worsen zinc deficiency in susceptible clients; monitor deficiency-risk context during extended therapy.
Cimetidine-Specific (H2 blocker)
- Drug interactions: warfarin, phenytoin, theophylline, metronidazole, and ketoconazole interaction pathways require review
- IV rapid bolus → cardiac arrhythmias and hypotension — always infuse over 15–20 minutes
- Rare endocrine/hematologic effects include gynecomastia and blood-count suppression syndromes (for example neutropenia/agranulocytosis) in high-risk pathways.
Nursing Interventions
- Administer oral PPIs 30–60 minutes before meals (activates in an acidic, stimulated environment)
- Never crush, chew, or break delayed-release/enteric-coated PPI formulations
- For omeprazole suspension/granules, dilute per product guidance and administer via oral or enteral-tube pathways as ordered.
- Pantoprazole granules: mix only in apple juice or applesauce; follow with sips of water
- For famotidine oral suspension, shake vigorously 5–10 seconds before each dose
- Verify pregnancy risk and contraception reliability before gastric-protection use of misoprostol in clients with childbearing potential.
- Teach misoprostol users to report abnormal vaginal bleeding or uterine cramping promptly.
- Monitor GI symptoms: weight, nausea, abdominal pain, bowel habits
- Monitor renal/hepatic function when clinically indicated and track prolonged-therapy micronutrient risks (magnesium, B12, and selected zinc-deficiency contexts with IV pantoprazole)
- Do not attribute chest pain automatically to reflux; perform focused cardiac assessment when chest-pain symptoms are present
- Patient education: avoid alcohol, NSAIDs, spicy foods; complete full course even if symptoms resolve
- Antacids may be taken short-term while PPIs are reaching full effect (takes several days)
- Teach bleeding-ulcer red flags requiring urgent escalation (hematemesis, coffee-ground emesis, melena, worsening severe pain)
PPI Administration Timing
PPIs must be taken 30–60 minutes before the first meal of the day — they are activated by the meal-stimulated proton pump. Taking them with food or after eating significantly reduces efficacy.
PPI Contraindication
PPIs are contraindicated with rilpivirine-containing HIV regimens due to clinically significant interaction risk.
Misoprostol Pregnancy Risk
For ulcer-prevention use, misoprostol is contraindicated in pregnancy because it can cause spontaneous abortion, premature birth, or fetal harm.
Related Concepts
- digestive-system — Normal gastric acid secretion physiology and mucosal protection.
- cholecystitis — Peptic ulcer disease in differential for upper abdominal pain.
- misoprostol - Prostaglandin analogue used for NSAID-ulcer prevention and multiple reproductive indications.
- diarrhea-assessment-and-management — C. difficile as a PPI-associated complication.
- nsaids — NSAIDs are a leading cause of peptic ulcer disease requiring PPI prophylaxis.
- acute-gastrointestinal-bleeding-in-critical-care - IV acid-suppression support context during active GI hemorrhage management.
Self-Check
- A patient is prescribed omeprazole 20 mg daily for GERD. When should the nurse instruct the patient to take this medication?
- What is the key difference in mechanism between PPIs and H2 blockers?
- A patient receiving IV cimetidine develops sudden bradycardia. What administration error may have occurred?